Guidelines for Antiepileptic Drug Discontinuation
Criteria for Considering Discontinuation
- A taper of antiepileptic drugs may be contemplated after at least two consecutive years of seizure freedom, with the decision made jointly by the clinician, the patient, and the family, taking clinical, social, and personal factors into account. 1
- The same minimum seizure‑free period (≥ 2 years) is required before a discontinuation attempt is recommended in the evidence base. 2
Factors Not Influencing the Discontinuation Decision
- Family history of epilepsy does not affect the decision to discontinue therapy. 2
- History of febrile seizures does not affect the decision to discontinue therapy. 2
- Duration or severity of the epilepsy does not affect the decision to discontinue therapy. 2
- Number and type of antiepileptic medications (when considered alone) do not affect the decision to discontinue therapy. 2
Special Clinical Situations
- In patients with neurocysticercosis who have experienced only a few seizures before antiparasitic treatment, have radiologic evidence of cyst resolution, and have achieved 24 consecutive months of seizure freedom, a gradual taper and discontinuation of antiepileptic drugs may be considered. 3
- For patients with solitary enhancing lesions (SELs) who have been seizure‑free for 6 months and whose lesion has resolved on imaging, a taper and discontinuation may be pursued provided no high‑risk features are present (e.g., residual cystic lesions or calcifications, breakthrough seizures, or more than two seizures). 3
Neurocysticercosis‑Specific Antiepileptic Drug Withdrawal Recommendations
Timing Criteria for Initiating Taper
- In patients with neurocysticercosis who had few seizures before treatment and whose cystic lesions have resolved on imaging, tapering of antiepileptic drugs should be considered after at least 24 months of seizure freedom. 4
- For neurocysticercosis patients presenting with a solitary enhancing lesion, tapering may be initiated after only 6 months of seizure freedom provided that imaging confirms lesion resolution and no high‑risk features are present (e.g., residual cysts, calcifications, breakthrough seizures, or more than two seizures overall). 4
Monitoring Requirements During Taper
- Magnetic resonance imaging (MRI) should be repeated at least every 6 months until complete resolution of any structural lesions is documented in neurocysticercosis cases. 4